研发中心 / R & D Center
| Established in March 2003, the Beijing Innovative Drug R&D Center of Betta Pharmaceuticals Co., Ltd. is located in Building 29 on No. 1 North Disheng Street, Beijing Economic and Technological Development Area and it has a 4000 square-meter laboratory building. There are a number of preclinical research departments including the Drug Synthesis Lab, Polypeptide Synthesis Lab, Analytical Lab, Pharmacology Lab, Regulatory Department, Quality Assurance Department and Formulation Lab as well as departments such as the Intellectual Property Department and the General Office in the center. It now has more than 100 in research staff, among which 9 are U.S. PhD returnees. Not only do they have deep academic credentials and competent understanding of innovative drug research and development, but they also have extensive experiences in this field. Among them, the chairman of the board/CEO, Dr. Ding Lieming, the president/chief scientist, Dr. Wang Yinxiang, the vice-president/chief medical officer, Dr. Tan Fenlai, the chief chemist, Dr. Hu Shaojing and the vice-president, Dr. Zhu Lingyu were all successively selected to the national “Recruitment Program of Global Experts”.|
For more than 10 years since its establishment, the R&D center has always been committed to the research and development of innovative drugs, including 6 first-class national innovative drugs and 16 third-class national innovative drugs, among which the Icotinib Hydrochloride Tablets, a class 1.1 innovative drug, has already received marketing approval fromChina Food and Drug Administration in June 2011. The grand launching press conference for Icotinib Hydrochloride Tablets (Trade Name: Conmana) was held at the Great Hall of the People in August 2011.
As the company's growth progresses, the R&D Center has attracted more and more talents. It’s now capable of completing a series of core work including drug synthesis, screening, analysis, formulation, pharmacology study and clinical research as well as registration. Moreover, the center now has the capacity of launching multiple innovative drug programs simultaneously.
The ongoing programs at the center cover various stages of drug development, such as preclinical study (which includes pharmacodynamic and pharmacokinetic studies, CMC, and safety evaluation), clinical study, regulatory submission and post marketing, thus forming a structured R&D organization. It currently has 22 programs under development. Among the 6 first class national innovative drugs, BPI-9016 has received clinical approval. The preclinical studies as well as the application for clinical trials of the other 5 programs are scheduled to be completed successively by 2016. Clinical trials for some of the other 16 third class innovative drugs and generic drugs have already been completed.